CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 151 enrolled
Drug / intervention
TH9507 human growth hormone releasing hormone (GHRH)drug
Likely dose
TH9507 human growth hormone releasing hormone (GHRH) 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00257712
NCT00257712Phase 2Completed
CompareCT.gov

GHRH: Cognition in Aging and MCI

University of Washington·interventional·Posted Nov 23, 2005·Updated Dec 19, 2013

In Brief

A Phase 2 clinical trial evaluating TH9507 human growth hormone releasing hormone (GHRH) for Aging and Mild Cognitive Impairment. Completed, enrolled 151 participants across 1 site.

Detailed Summary

The purpose of the SMART study was to better understand whether the body's own production of growth hormone (GH) would improve memory and problem solving ability, or cognitive function. The study was a double blind, placebo-controlled study of the cognitive effects of growth hormone releasing hormone (GHRH) in healthy older men and women and in those with mild cognitive impairment (MCI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAging, Mild Cognitive Impairment
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 23, 2005
Enrollment StartFeb 1, 2006
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 20.6 years ago

Interventions

TH9507 human growth hormone releasing hormone (GHRH)drug

1mg subcutaneous injection given daily for 20 weeks